Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Allergy ; 61(3): 316-20, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16436140

ABSTRACT

This guideline is the result of a consensus reached during a panel discussion at the 2nd International Consensus Meeting on Urticaria, Urticaria 2004, a joint initiative of the European Academy of Allergology and Clinical Immunology Dermatology Section and the European Union (EU)-funded network of excellence, GA2LEN. It covers the definition and classification of urticaria, taking into account the recent progress in identifying causes, eliciting factors and pathomechanisms of this disease. We have outlined useful diagnostic approaches for different subtypes of urticaria. This guideline was, in addition, accepted by the European Dermatology Forum (EDF) and was formally approved by the European Union of Medical Specialists (UEMS).


Subject(s)
Urticaria/classification , Urticaria/diagnosis , Allergens/adverse effects , Europe , Female , Humans , Hypersensitivity, Immediate/classification , Hypersensitivity, Immediate/diagnosis , Male , Prevalence , Risk Factors , Sensitivity and Specificity , Severity of Illness Index , Skin Tests , Urticaria/epidemiology
2.
Allergy ; 61(3): 321-31, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16436141

ABSTRACT

This guideline is the result of a consensus reached during a panel discussion at the second International Consensus Meeting on Urticara, Urticaria 2004, a joint initiative of the EAACI Dermatology Section and GA2LEN. Urticaria has a profound impact on the quality of life, and effective treatment is therefore required. The recommended first line treatment are nonsedating H1 antihistamines. They have proven to be effective in double-blind controlled studies, but dosages increased up to fourfold over the recommended doses may be necessary. However, for different urticaria subtypes and in view of individual variation in the course of the disease and response to treatment, additional or alternative therapies may be required. Immunosuppressive drugs like cyclosporin A and corticosteroids are not recommended for long-term treatment due to unavoidable severe adverse effects. This guideline was, in addition, accepted by the European Dermatology Forum (EDF) and formally approved by the European Union of Medical Specialists (UEMS).


Subject(s)
Anti-Allergic Agents/therapeutic use , Diet , Immunosuppressive Agents/therapeutic use , Quality of Life , Urticaria/therapy , Combined Modality Therapy , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , Histamine H1 Antagonists/therapeutic use , Humans , Life Style , Male , Randomized Controlled Trials as Topic , Risk Assessment , Severity of Illness Index , Treatment Outcome , Urticaria/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...